Loading stock data…
BillionToOne, Inc. (BLLN)
$99.06-0.33 (-0.33%)
Market ClosedLast close Sep 8
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BillionToOne, Inc. in the Healthcare sector is trading at $99.06 with a market capitalization of $4.7B. Wall Street consensus targets $119.75 (8 analysts), implying a +20.9% move over the next 12 months. The stock is currently 34% below its 52-week high of $150.44, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $108.39M↑ | $96.05M↑ | $83.52M↑ | $66.57M↑ | $58.96M |
| Gross Profit | $79.10M↑ | $68.60M↑ | $58.42M↑ | $43.47M↑ | $37.97M |
| Operating Income | $17.83M↑ | $10.33M↑ | $9.63M↑ | -$1.63M↑ | -$2.31M |
| Net Income | $17.97M↑ | $5.98M↑ | $5.71M↑ | -$246,000↑ | -$3.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
138.04
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.03%
Volume
Today's trading volume
590,275
Recent News
Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million
The molecular diagnostics company reported a notable insider stock sale.
BillionToOne (BLLN) Q2 2026 Earnings Call Transcript
Oncology tests surged 176% while prenatal revenue climbed 55%, driving 64% overall growth.
Why BillionToOne Plummeted 38%, Leading A Medtech Sell-Off
Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.
Can BillionToOne (BLLN) Justify Its Price On Earnings And Reaffirmed 2026 Guidance?
BillionToOne (BLLN) is back in focus after its August 5 update, when the company reported second quarter 2026 results and reaffirmed its full-year revenue outlook in the mid US$400 million range. See our latest analysis for BillionToOne. The recent earnings beat and reiterated 2026 revenue guidance have been met with strong buying interest, with BillionToOne’s share price return of 61.4% over 90 days and 68.0% year to date signaling firm positive momentum. If BillionToOne’s move has caught...